비경구 영양 시장 규모, 점유율, 동향 분석 보고서 : 영양소별, 투여 단계별, 적응증별, 판매 채널별, 지역별, 부문별 예측(2026-2033년)

Parenteral Nutrition Market Summary

The global parenteral nutrition market size was estimated at USD 7.97 billion in 2025 and is projected to reach USD 12.59 billion by 2033, growing at a CAGR of 5.87% from 2026 to 2033. This growth is attributed to the rising prevalence of gastrointestinal disorders, increasing premature births, and the growing incidence of chronic diseases such as cancer.

Expanding hospital infrastructure, advancements in nutrient formulations, and increasing adoption of home parenteral nutrition further support market growth globally. Moreover, the rising prevalence of chronic conditions, particularly cancer and disease-related malnutrition, is driving demand for parenteral nutrition, as these patients often experience gastrointestinal dysfunction or treatment-related complications that limit oral or enteral feeding. Cancer therapies such as chemotherapy and radiation frequently necessitate intravenous nutritional support; for instance, the National Cancer Institute estimates 2,114,850 new cancer cases and 626,140 cancer deaths in the U.S. in 2026, highlighting the growing patient base requiring parenteral nutrition.

Numerous benefits accompany parenteral nutrition, including ease of use, stimulation of stomach blood flow, efficient nutrient delivery, and preservation of muscle catabolism. Globally, various health awareness campaigns, with a particular emphasis on nutrition, are underway, along with diverse initiatives promoting health and social care, expected to bolster market growth. For example, India observed POSHAN Maah in September 2023, mirroring the Government of India's flagship program, POSHAN Abhiyaan, aimed at raising awareness and enhancing nutritional outcomes for pregnant women, children under six years of age, and lactating mothers.

PN also has applications for infants and children suffering from a disease or medical condition, thereby requiring special nutritional management. In 2023, Specialized Nutrition Europe (SNE) estimated that nearly 300,000 EU children are anticipated to require medical nutrition for their special medical needs in early life stages, which supports growth and development. The study further reveals that about 40% of hospitalized adult patients are malnourished and need medical nutrition to manage the disease-related malnutrition condition, thereby reducing the duration of hospital stay. PN lowers the infection risk and underdevelopment, thereby promoting its adoption worldwide.

Parenteral nutrition providers are increasingly focusing on ready-to-use multi-chamber bags, advanced lipid emulsions, and patient-specific formulations to improve safety, efficiency, and clinical outcomes. Companies like Baxter and Fresenius Kabi offer specialized solutions such as Numeta for neonates, Kabiven for adults, and SMOFlipid/Omegaven lipid emulsions enriched with mixed oils and omega-3s to support metabolic function and reduce complications. There is also a growing emphasis on tailored neonatal and pediatric PN, home parenteral nutrition, and streamlined infusion workflows, reflecting the industry's shift toward protocol-driven, patient-centric nutrition management across hospital and outpatient settings.

Many premature babies experience low weight and underdeveloped immunity, placing them at significant risk. There is extensive focus from individuals and healthcare authorities on reducing mortality associated with preterm birth, which drives the utilization of parenteral lipid emulsions. According to the U.S. Centers for Disease Control and Prevention (CDC), the preterm birth rate in the country was approximately 10.4% in 2022. In addition, during the same period, the preterm birth rate for African American women was around 14.6%. These elevated preterm birth rates are expected to bolster market expansion.

Global Parenteral Nutrition Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global parenteral nutrition market report based on nutrient type, stage type, indication, sales channel, and region:

• Nutrient Type Outlook (Revenue, USD Million, 2021 - 2033)
• Carbohydrates
• Parenteral Lipid Emulsion
• Single Dose Amino Acid Solution
• Trace Elements
• Vitamins & Minerals
• Stage Type Outlook (Revenue, USD Million, 2021 - 2033)
• Adult
• Pediatrics
• Indication Outlook (Revenue, USD Million, 2021 - 2033)
• Alzheimer's
• Nutrition Deficiency
• Cancer Care
• Diabetes
• Chronic Kidney Diseases
• Orphan Diseases
• Dysphagia
• Pain Management
• Malabsorption/GI Disorder/Diarrhea
• Others
• Sales Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Online
• Retail
• Institutional
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Sweden
  • Norway
  • Denmark
• Asia Pacific
  • China
  • India
  • Japan
  • Thailand
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
• 1.5. Details of primary research
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.1.1. Approach 1: Commodity flow approach
  • 1.7.2. Volume price analysis (Model 2)
    • 1.7.2.1. Approach 2: Volume price analysis
• 1.8. Research Scope and Assumptions
  • 1.8.1. List of Secondary Sources
  • 1.8.2. List of Primary Sources
  • 1.8.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Nutrition Type Outlook
  • 2.2.2. Stage Type Outlook
  • 2.2.3. Indication Outlook
  • 2.2.4. Sales Channel Outlook
• 2.3. Competitive Insights

Chapter 3. Parenteral Nutrition Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Industry Analysis
  • 3.2.1. User Perspective Analysis
  • 3.2.2. Key End Users
• 3.3. Technology Outlook
• 3.4. Regulatory Framework
• 3.5. Market Dynamics
  • 3.5.1. Market Drivers Analysis
    • 3.5.1.1. Rising Prevalence of Gastrointestinal Disorders and Malabsorption Conditions
    • 3.5.1.2. Increasing Number of Preterm Births Requiring Neonatal Nutritional Support
    • 3.5.1.3. Growing Incidence of Cancer and Demand for Clinical Nutritional Support
    • 3.5.1.4. Expansion of Home Parenteral Nutrition (HPN) Programs
    • 3.5.1.5. Rising Hospital Admissions and Critical Care Patient Population
    • 3.5.1.6. Increasing Awareness of Clinical Nutrition in Disease Management
    • 3.5.1.7. Growing Geriatric Population with Nutritional Deficiencies
  • 3.5.2. Market Restraints Analysis
    • 3.5.2.1. Stringent Regulatory Requirements for Sterile Compounding
    • 3.5.2.2. Risk of Metabolic and Liver-Related Complications
  • 3.5.3. Industry Challenges and Opportunity Analysis
• 3.6. Parenteral Nutrition Market Analysis Tools
  • 3.6.1. Porter's Analysis
    • 3.6.1.1. Bargaining power of the suppliers
    • 3.6.1.2. Bargaining power of the buyers
    • 3.6.1.3. Threats of substitution
    • 3.6.1.4. Threats from new entrants
    • 3.6.1.5. Competitive rivalry
  • 3.6.2. PESTEL Analysis
    • 3.6.2.1. Political landscape
    • 3.6.2.2. Economic and Social landscape
    • 3.6.2.3. Technological landscape
    • 3.6.2.4. Environmental landscape
    • 3.6.2.5. Legal landscape

Chapter 4. Parenteral Nutrition Market: Nutrient Type Estimates & Trend Analysis

• 4.1. Definition and Scope
• 4.2. Nutrient Type Market Share Analysis, 2025 & 2033
• 4.3. Segment Dashboard
• 4.4. Parenteral Nutrition Market: By Nutrient Type, 2021 to 2033
• 4.5. Carbohydrates
  • 4.5.1. Carbohydrates Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Parenteral Lipid Emulsion
  • 4.6.1. Parenteral Lipid Emulsion Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Single Dose Amino Acid Solution
  • 4.7.1. Single Dose Amino Acid Solution Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Trace Elements
  • 4.8.1. Trace Elements Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.9. Vitamins & Minerals
  • 4.9.1. Vitamins & Minerals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Parenteral Nutrition Market: Stage Type Estimates & Trend Analysis

• 5.1. Definition and Scope
• 5.2. Stage Type Market Share Analysis, 2025 & 2033
• 5.3. Segment Dashboard
• 5.4. Parenteral Nutrition Market: By Stage Type, 2021 to 2033
• 5.5. Adult
  • 5.5.1. Adult Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Pediatric
  • 5.6.1. Pediatric Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Parenteral Nutrition Market: Indication Estimates & Trend Analysis

• 6.1. Definition and Scope
• 6.2. Indication Market Share Analysis, 2025 & 2033
• 6.3. Segment Dashboard
• 6.4. Parenteral Nutrition Market: By Indication, 2021 to 2033
• 6.5. Alzheimer's
  • 6.5.1. Alzheimer's Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Nutrition Deficiency
  • 6.6.1. Nutrition Deficiency Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Cancer Care
  • 6.7.1. Cancer Care Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Diabetes
  • 6.8.1. Diabetes Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.9. Chronic Kidney Disease
  • 6.9.1. Chronic Kidney Disease Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.10. Orphan Diseases
  • 6.10.1. Orphan Diseases Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.11. Dysphagia
  • 6.11.1. Dysphagia Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.12. Pain Management
  • 6.12.1. Pain Management Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.13. Malabsorption/GI Disorder/Diarrhea
  • 6.13.1. Malabsorption/GI Disorder/Diarrhea Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.14. Others
  • 6.14.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Parenteral Nutrition Market: Sales Channel Estimates& Trend Analysis

• 7.1. Definition and Scope
• 7.2. Sales Channel Market Share Analysis, 2025 & 2033
• 7.3. Segment Dashboard
• 7.4. Parenteral Nutrition Market: By Sales Channel, 2021 to 2033
• 7.5. Online
  • 7.5.1. Online Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Retail
  • 7.6.1. Retail Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Institutional
  • 7.7.1. Institutional Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Parenteral Nutrition Market: Regional Estimates & Trend Analysis by Country, Nutrient Type, Stage Type, Indication, and Sales Channel

• 8.1. Definition and Scope
• 8.2. Regional Market Share Analysis, 2025 & 2033
• 8.3. Regional Market Dashboard
• 8.4. Regional Market Snapshot
• 8.5. Parenteral Nutrition Market Share, By Region, 2025 & 2033 (USD Million)
• 8.6. North America
  • 8.6.1. North America Parenteral Nutrition Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. U.S.
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Regulatory Landscape/Reimbursement Scenario
    • 8.6.2.3. Competitive Insights
    • 8.6.2.4. U.S. Parenteral Nutrition Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. Canada
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Regulatory Landscape/Reimbursement Scenario
    • 8.6.3.3. Competitive Insights
    • 8.6.3.4. Canada Parenteral Nutrition Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.4. Mexico
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Regulatory Landscape/Reimbursement Scenario
    • 8.6.4.3. Competitive Insights
    • 8.6.4.4. Mexico Parenteral Nutrition Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. Europe
  • 8.7.1. Europe Parenteral Nutrition Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. UK
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Regulatory Landscape/Reimbursement Scenario
    • 8.7.2.3. Competitive Insights
    • 8.7.2.4. UK Parenteral Nutrition Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. Germany
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Regulatory Landscape/Reimbursement Scenario
    • 8.7.3.3. Competitive Insights
    • 8.7.3.4. Germany Parenteral Nutrition Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.4. France
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Regulatory Landscape/Reimbursement Scenario
    • 8.7.4.3. Competitive Insights
    • 8.7.4.4. France Parenteral Nutrition Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.5. Italy
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Regulatory Landscape/Reimbursement Scenario
    • 8.7.5.3. Competitive Insights
    • 8.7.5.4. Italy Parenteral Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.6. Spain
    • 8.7.6.1. Key Country Dynamics
    • 8.7.6.2. Regulatory Landscape/Reimbursement Scenario
    • 8.7.6.3. Competitive Insights
    • 8.7.6.4. Spain Parenteral Nutrition Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.7. Sweden
    • 8.7.7.1. Key Country Dynamics
    • 8.7.7.2. Regulatory Landscape/Reimbursement Scenario
    • 8.7.7.3. Competitive Insights
    • 8.7.7.4. Sweden Parenteral Nutrition Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.8. Denmark
    • 8.7.8.1. Key Country Dynamics
    • 8.7.8.2. Regulatory Landscape/Reimbursement Scenario
    • 8.7.8.3. Competitive Insights
    • 8.7.8.4. Denmark Parenteral Nutrition Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.9. Norway
    • 8.7.9.1. Key Country Dynamics
    • 8.7.9.2. Regulatory Landscape/Reimbursement Scenario
    • 8.7.9.3. Competitive Insights
    • 8.7.9.4. Norway Parenteral Nutrition Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.8. Asia Pacific
  • 8.8.1. Asia Pacific Parenteral Nutrition Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.2. China
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Regulatory Landscape/Reimbursement Scenario
    • 8.8.2.3. Competitive Insights
    • 8.8.2.4. China Parenteral Nutrition Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.3. Japan
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Regulatory Landscape/Reimbursement Scenario
    • 8.8.3.3. Competitive Insights
    • 8.8.3.4. Japan Parenteral Nutrition Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.4. India
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Regulatory Landscape/Reimbursement Scenario
    • 8.8.4.3. Competitive Insights
    • 8.8.4.4. India Parenteral Nutrition Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.5. South Korea
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Regulatory Landscape/Reimbursement Scenario
    • 8.8.5.3. Competitive Insights
    • 8.8.5.4. South Korea Parenteral Nutrition Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.6. Australia
    • 8.8.6.1. Key Country Dynamics
    • 8.8.6.2. Regulatory Landscape/Reimbursement Scenario
    • 8.8.6.3. Competitive Insights
    • 8.8.6.4. Australia Parenteral Nutrition Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.7. Thailand
    • 8.8.7.1. Key Country Dynamics
    • 8.8.7.2. Regulatory Landscape/Reimbursement Scenario
    • 8.8.7.3. Competitive Insights
    • 8.8.7.4. Thailand Parenteral Nutrition Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.9. Latin America
  • 8.9.1. Latin America Parenteral Nutrition Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.9.2. Brazil
    • 8.9.2.1. Key Country Dynamics
    • 8.9.2.2. Regulatory Landscape/Reimbursement Scenario
    • 8.9.2.3. Competitive Insights
    • 8.9.2.4. Brazil Parenteral Nutrition Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.9.3. Argentina
    • 8.9.3.1. Key Country Dynamics
    • 8.9.3.2. Regulatory Landscape/Reimbursement Scenario
    • 8.9.3.3. Competitive Insights
    • 8.9.3.4. Argentina Parenteral Nutrition Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.10. Middle East and Africa
  • 8.10.1. Middle East and Africa Parenteral Nutrition Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.10.2. Saudi Arabia
    • 8.10.2.1. Key Country Dynamics
    • 8.10.2.2. Regulatory Landscape/Reimbursement Scenario
    • 8.10.2.3. Competitive Insights
    • 8.10.2.4. Saudi Arabia Parenteral Nutrition Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.10.3. UAE
    • 8.10.3.1. Key Country Dynamics
    • 8.10.3.2. Regulatory Landscape/Reimbursement Scenario
    • 8.10.3.3. Competitive Insights
    • 8.10.3.4. UAE Parenteral Nutrition Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.10.4. South Africa
    • 8.10.4.1. Key Country Dynamics
    • 8.10.4.2. Regulatory Landscape/Reimbursement Scenario
    • 8.10.4.3. Competitive Insights
    • 8.10.4.4. South Africa Parenteral Nutrition Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.10.5. Kuwait
    • 8.10.5.1. Key Country Dynamics
    • 8.10.5.2. Regulatory Landscape/Reimbursement Scenario
    • 8.10.5.3. Competitive Insights
    • 8.10.5.4. Kuwait Parenteral Nutrition Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis by Key Market Participants
• 9.2. Company Categorization
• 9.3. Company Market Share Analysis, 2025
• 9.4. Company Position Analysis, 2025
• 9.5. Company Profiles
  • 9.5.1. Baxter
    • 9.5.1.1. Company Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic initiatives
  • 9.5.2. Otsuka Pharmaceutical Factory, Inc.
    • 9.5.2.1. Company Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic initiatives
  • 9.5.3. Grifols, S.A.
    • 9.5.3.1. Company Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic initiatives
  • 9.5.4. B. Braun Melsungen AG
    • 9.5.4.1. Company Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic initiatives
  • 9.5.5. Vifor Pharma (Acquired by CSL)
    • 9.5.5.1. Company Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic initiatives
  • 9.5.6. Fresenius Kabi AG
    • 9.5.6.1. Company Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic initiatives
  • 9.5.7. Sichuan Kelun Pharmaceutical Co., Ltd.
    • 9.5.7.1. Company Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic initiatives
  • 9.5.8. Pfizer Inc. (Hospira Inc.)
    • 9.5.8.1. Company Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic initiatives
  • 9.5.9. ICU Medical, Inc.
    • 9.5.9.1. Company Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic initiatives
  • 9.5.10. JW Pharmaceutical
    • 9.5.10.1. Company Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Strategic initiatives
  • 9.5.11. Aculife
    • 9.5.11.1. Company Overview
    • 9.5.11.2. Financial Performance
    • 9.5.11.3. Product Benchmarking
    • 9.5.11.4. Strategic initiatives